1350711-78-2

Basic information

• Product Name: methyl (1R,2R,4R)-2-(4-bromophenyl)-4-morpholin-4-ylcyclohexanecarboxylate
• Synonyms: methyl (1R,2R,4R)-2-(4-bromophenyl)-4-morpholin-4-ylcyclohexanecarboxylate
• CAS NO: 1350711-78-2
• Molecular Weight: 382.297
• Mol File: 1350711-78-2.mol

Chemical Properties

• CAS DataBase Reference: methyl (1R,2R,4R)-2-(4-bromophenyl)-4-morpholin-4-ylcyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (1R,2R,4R)-2-(4-bromophenyl)-4-morpholin-4-ylcyclohexanecarboxylate(1350711-78-2)
• EPA Substance Registry System: methyl (1R,2R,4R)-2-(4-bromophenyl)-4-morpholin-4-ylcyclohexanecarboxylate(1350711-78-2)

Safety Data

• Hazardous Substances Data: 1350711-78-2(Hazardous Substances Data)

Upstream product

• 1350711-68-0 (1R,2R)-2-(4-bromophenyl)-4-oxocyclohexanecarboxylic acid 
• 1350711-74-8 N-cyclohexylcyclohexanaminium (1R,2R)-2-(4-bromophenyl)-4-oxocyclohexane-carboxylate 
• 1350711-72-6 (4R)-4-benzyl-3-{[(1R,2R)-2-(4-bromophenyl)-4-oxocyclohexyl]carbonyl}-1,3-oxazolidin-2-one 
• 27465-66-3 4-bromocinnamoyl chloride 
• 1200-07-3 trans-4-bromocinnamic acid 
• 110-91-8 morpholine 
• 1350711-76-0 methyl (1R,2R)-2-(4-bromophenyl)-4-oxocyclohexanecarboxylate 

Downstream Products

• 1350711-40-8 4-[(1R,3R,4R)-4-{[bis(4-fluorophenyl)methyl]carbamoyl}-3-(4-cyanophenyl)cyclohexyl]-morpholine trifluoroacetate 
• 1350711-82-8 (1R,2R,4R)-2-(4-bromophenyl)-4-morpholin-4-ylcyclohexanecarboxylic acid hydrochloride 
• 1350710-24-5 (1R,2R,4R)-N-[bis(4-fluorophenyl)methyl]-2-(4-bromophenyl)-4-(morpholin-4-yl)cyclohexanecarboxamide 

Relevant articles and documents

Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors

The synthesis, SAR, binding affinities and pharmacokinetic profiles are described for a series of cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors discovered by high throughput screening. Compounds show high levels of ex vivo target engagement in mouse plasma 20 h post oral dose.

NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, incl